Disc Medicine (Disc) has secured a $200m non-dilutive term loan facility from Hercules Capital to advance the clinical trials of assets across its portfolio.

Through the financing, the company also aims to further bolster its financial and operational flexibility.

The loan facility comprises up to four tranches, with a $30m tranche already drawn at closing and further funds available through H2 2026 at Disc’s option.

An additional $80m is available at Disc’s discretion, with another $65m contingent on attaining certain performance milestones.

The final tranche of $25m will be accessible during the interest-only period, subject to the consent of Hercules Capital.

The funding is set to support various activities, including the launch of a confirmatory study of bitopertin for erythropoietic protoporphyria (EPP), Phase II studies for DISC-0974 and DISC-3405 in anaemia of myelofibrosis (MF) and in polycythaemia vera (PV), respectively.

The company also plans to commence a multiple dose trial in anaemia of non-dialysis dependent chronic kidney disease (NDD-CKD).

Disc Medicine chief financial officer Jean Franchi said: “With this non-dilutive $200m financing, we are well-positioned as we prepare for upcoming catalysts across our entire pipeline including the potential initiation of a confirmatory trial of bitopertin in EPP by mid-2025 and related commercial preparations.

“Not only does this non-dilutive financing strengthen what we believe to be an already strong financial position, it provides optionality and strategic flexibility in future capital formation as we continue to advance our pipeline in pursuit of our mission to deliver innovative treatments to patients suffering from serious hematologic diseases.”

Recently, the company announced a US Food and Drug Administration (FDA) agreement on the regulatory path for bitopertin in treating the rare skin condition erythropoietic protoporphyria (EPP).

"Disc Medicine secures $200m financing to support trials" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

 

The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.